earnings
confidence high
sentiment positive
materiality 0.85
PerkinElmer Q2 revenue $1.228B (+51%); raises guidance; to acquire BioLegend
REVVITY, INC.
2021-Q2 EPS reported
$5.56
revenue$910,747,000
- Revenue $1.228B, +51% reported, +41% organic; GAAP EPS $2.19, adjusted EPS $2.83.
- Raises full-year revenue and earnings guidance; initiates Q3 guidance.
- Agrees to acquire BioLegend, a leading antibody & research reagent provider.
- GAAP operating margin 27.1% (vs 21.6% Q2 2020); adjusted margin 33.5% (vs 28.1%).
- Earnings call moved to July 26 at 8:00 a.m. ET.